In the face of increasingly complex internal and external environments, China's biopharmaceutical industry has chosen 'going global' as a key development strategy to increase revenue, enhance competitiveness, and boost brand value. On the path towards international markets, Chinese biopharmaceutical companies are constantly seeking balance and breakthroughs, moving towards higher points on the value chain. While new opportunities emerge continuously, they also face numerous challenges. The global biopharmaceutical industry pattern is evolving, with intensified competition for core elements such as talent and technology internationally, accelerating the reshaping of industrial chains and supply chains. In addition, during this process, it is necessary to deal with differences in quality standards, intellectual property disputes, market access difficulties, etc., while also bearing the pressure of cost control and R&D innovation.
Frost & Sullivan (Frost & Sullivan, abbreviated as 'Frost & Sullivan') has joined hands with Cytiva, a global technology service provider, to release the '2025 China Biopharmaceutical Going Global Trend Blue Book'. The aim is to track the process of Chinese biopharmaceutical companies going global, analyze the driving factors and challenges for accelerating overseas layout. At the same time, the Blue Book will comprehensively and multi-dimensionally discuss and consider the go-to-market models, development directions, and buyer value orientations of Chinese biopharmaceuticals, sharing valuable insights and references with industry stakeholders and investors, and jointly drawing a blueprint for the international development of Chinese biopharmaceuticals with all parties in the industry.
